Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 78
Filtrar
1.
Eur J Pharmacol ; 868: 172871, 2020 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-31846627

RESUMO

Niacin has been widely used as an antihyperlipidemic drug, but the flushing effect restricted its clinical application. Here, we developed novel niacin-lipoic acid dimers which lead to better lipid modulation, higher synergistic effects and less side effects. We utilized molecular docking simulation to design a novel series of niacin-lipoic acid dimers. The compound N-(2-(5-(1,2-dithiolan-3-yl)pentanamido)ethyl)nicotinamide (N2L) was selected for the in vitro and in vivo evaluation, including the agonist activity in CHO-hGPR109A cells, cell protective effects in HT22 and HUVECs cells, flushing effect in guinea pigs and rats, lipid modulation in C57BL/6 mice and high fat diet-rats and atherosclerotic lesions regulation in apolipoprotein E null mice. N2L worked as potent and selective agonists for the high affinity niacin receptor GPR109A. N2L retained antioxidation and cytoprotection of lipoic acid. In addition, N2L displayed a good therapeutic index regarding lipid modulation and atherosclerotic lesions regulation, and minimized niacin-induced vasodilation (flushing) effect in vivo. N2L showed effective treatment regarding to lipid regulation and atherosclerosis inhibition effects, also with excellent antioxidant effects, safety profiles and non-flushing. All these results suggest N2L promising application prospects in the drug development for the treatment of atherosclerosis.


Assuntos
Aterosclerose/tratamento farmacológico , Dislipidemias/tratamento farmacológico , Rubor/prevenção & controle , Hipolipemiantes/farmacologia , Animais , Aterosclerose/sangue , Aterosclerose/diagnóstico , Linhagem Celular , Cricetulus , Dimerização , Modelos Animais de Doenças , Desenho de Fármacos , Dislipidemias/sangue , Dislipidemias/diagnóstico , Feminino , Rubor/induzido quimicamente , Células Endoteliais da Veia Umbilical Humana , Humanos , Hipolipemiantes/química , Hipolipemiantes/uso terapêutico , Lipídeos/sangue , Masculino , Camundongos , Camundongos Knockout para ApoE , Simulação de Acoplamento Molecular , Niacina/química , Niacina/farmacologia , Niacina/uso terapêutico , Ratos , Ácido Tióctico/química , Ácido Tióctico/farmacologia , Ácido Tióctico/uso terapêutico
2.
JAMA Dermatol ; 156(2): 182-185, 2020 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-31799996

RESUMO

Importance: Alcohol flushing syndrome (AFS, also known as Asian glow and Asian flush) affects 20% to 47% of East Asians and causes significant psychosocial distress. There are no approved treatments for this condition. Objective: To determine whether brimonidine gel, 0.33%, decreases facial erythema in patients with AFS after consumption of alcohol. Design, Setting, and Participants: In this randomized clinical trial, 20 healthy volunteers of East Asian descent with a self-reported history of AFS were recruited between April 2018 and March 2019. Interventions: Participants were randomized to application of brimonidine gel to either the left or right half of their face. Placebo control was applied to the opposite side. After 30 minutes, participants ingested alcohol. Main Outcomes and Measures: Outcomes were specified before data collection. The difference in erythema between the treated and placebo side of each participant's face was measured 60 minutes after drug application (primary outcome) and at 90 and 120 minutes after drug application (secondary outcomes). Participants were asked to rate their likelihood of using the medication again and their likelihood of recommending the medication to a friend on a scale of 0 to 10. Results: The mean (SD) age of the 20 individuals enrolled in the study was 30.5 (8.4) years, and there were 10 women (50%). There was a significant difference in erythema at 60 minutes after drug application as measured by the difference in Clinician Erythema Assessment score (2.1; 95% CI, 1.5-2.71; P < .001) and by the difference in Subject Self-Assessment score (1.7; 95% CI, 1.1- 2.3; P < .001). This effect persisted at 90 and 120 minutes. Individuals were likely to use the medication again (7.2; 95% CI, 6.0-8.3) and would also recommend it to a friend (7.6; 95% CI, 6.5-8.6). Conclusions and Relevance: This study demonstrates that brimonidine gel is effective in reducing the facial erythema of AFS. Patients with psychosocial distress due to AFS may benefit from treatment with brimonidine. Trial Registration: ClinicalTrials.gov identifier: NCT03497442.


Assuntos
Consumo de Bebidas Alcoólicas/efeitos adversos , Tartarato de Brimonidina/administração & dosagem , Etanol/efeitos adversos , Rubor/prevenção & controle , Administração Cutânea , Adulto , Povo Asiático , Tartarato de Brimonidina/farmacologia , Método Duplo-Cego , Etanol/administração & dosagem , Feminino , Rubor/etiologia , Géis , Humanos , Masculino , Estudos Prospectivos , Adulto Jovem
3.
Am J Health Syst Pharm ; 76(21): 1749-1752, 2019 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-31612928

RESUMO

PURPOSE: The options for immunotherapy treatment are limited for treatment of hepatocellular carcinoma. In this case study, we report a case of successful alternation of one PD-1 inhibitor for another after a hypersensitivity reaction. SUMMARY: Nivolumab (Opdivo, Bristol-Myers Squibb) has been Food and Drug Administration (FDA) approved for a variety of malignancies, including a recent approval for hepatocellular carcinoma (HCC). Infusion-related reactions occur in less than 1% of patients, and although such reactions are rare, recognition of infusion-related reactions induced by nivolumab is an important aspect of its usage. The PD-1 checkpoint inhibitor pembrolizumab is also FDA approved for subsequent-line therapy in treatment of HCC. Thus far, approximately 0.2% of patients experienced severe infusion-related reaction in studies using pembrolizumab. A 70-year-old male with HCC had an infusion reaction to nivolumab that presented as facial flushing, dyspnea, and back pain. The patient received prompt administration of diphenhydramine and hydrocortisone, which led to the amelioration of symptoms and allowed the patient to complete his immunotherapy treatment. For the third dose of nivolumab, the patient received premedications prior to treatment, including diphenhydramine, hydrocortisone, and famotidine. During his infusion, the patient experienced facial flushing, coughing, chest tightness, and an itchy throat. The patient again received diphenhydramine and hydrocortisone to treat infusion-related symptoms and his therapy was discontinued. Because of the nivolumab infusion-related reaction, nivolumab was discontinued, and the patient was started on pembrolizumab. The patient tolerated pembrolizumab without any subsequent infusion-related reactions. Prompt recognition and attention to immunotherapy infusion-related reactions could potentially prevent the fatal complication of anaphylaxis with immune checkpoint inhibitors. In this report, we describe the successful transition from one anti-PD-1 therapy to another for continued immunotherapy treatment without any subsequent infusion reactions. CONCLUSION: A patient with HCC was successfully treated with pembrolizumab after experiencing adverse effects with nivolumab.


Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Antineoplásicos Imunológicos/administração & dosagem , Carcinoma Hepatocelular/tratamento farmacológico , Hipersensibilidade a Drogas/etiologia , Neoplasias Hepáticas/tratamento farmacológico , Nivolumabe/efeitos adversos , Idoso , Antineoplásicos Imunológicos/efeitos adversos , Carcinoma Hepatocelular/imunologia , Tosse/induzido quimicamente , Tosse/imunologia , Tosse/prevenção & controle , Hipersensibilidade a Drogas/imunologia , Hipersensibilidade a Drogas/prevenção & controle , Substituição de Medicamentos , Rubor/induzido quimicamente , Rubor/imunologia , Rubor/prevenção & controle , Humanos , Infusões Intravenosas/efeitos adversos , Neoplasias Hepáticas/imunologia , Masculino , Nivolumabe/administração & dosagem , Receptor de Morte Celular Programada 1/antagonistas & inibidores , Receptor de Morte Celular Programada 1/imunologia
4.
Crit Care ; 22(1): 163, 2018 06 15.
Artigo em Inglês | MEDLINE | ID: mdl-29907121

RESUMO

Extracorporeal membrane oxygenation (ECMO) is used in critically ill patients with severe pulmonary and/or cardiac failure. Blood is drained from the venous system and pumped through a membrane oxygenator where it is oxygenated. For pulmonary support, the blood is returned to the patient via a vein (veno-venous ECMO) and for pulmonary/circulatory support it is returned via an artery (veno-arterial ECMO).Veno-venous ECMO can be performed either with a single dual-lumen cannula or with two separate single-lumen cannulas. If the latter is chosen, flow direction can either be from the inferior caval vein (IVC) to the right atrium or the opposite. Earlier research has shown that drainage from the IVC yields less recirculation and therefore the IVC to right atrium route has become the standard in most centers for veno-venous ECMO with two cannulas. However, recent research has shown that recirculation can be minimized using a multistage draining cannula in the optimal position inserted via the right internal jugular vein and with blood return to the femoral vein. The clinical results with this route are excellent.In veno-arterial ECMO the most common site for blood infusion is the femoral artery. If venous blood is drained from the IVC, the patient is at risk of developing a dual circulation (Harlequin syndrome, North-South syndrome, differential oxygenation) meaning a poor oxygenation of the upper part of the body, while the lower part has excellent oxygenation. By instead draining from the superior caval vein (SVC) via a multistage cannula inserted in the right internal jugular vein this risk is neutralized.In conclusion, the authors argue that draining blood from the SVC and right atrium via a multistage cannula inserted in the right internal jugular vein is equal or better than IVC drainage both in veno-venous two cannula ECMO and in veno-arterial ECMO with blood return to the femoral artery.


Assuntos
Cateterismo/instrumentação , Oxigenação por Membrana Extracorpórea/métodos , Posicionamento do Paciente/normas , Veia Cava Inferior/fisiologia , Adulto , Doenças do Sistema Nervoso Autônomo/etiologia , Doenças do Sistema Nervoso Autônomo/prevenção & controle , Cânula/tendências , Cateterismo/métodos , Drenagem/métodos , Rubor/etiologia , Rubor/prevenção & controle , Humanos , Hipo-Hidrose/etiologia , Hipo-Hidrose/prevenção & controle , Posicionamento do Paciente/métodos , Posicionamento do Paciente/tendências , Insuficiência Respiratória/terapia
6.
Oncologist ; 23(1): 16-24, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29038234

RESUMO

BACKGROUND: In the double-blind (DB) ELECT study, lanreotide depot/autogel significantly reduced versus placebo the need for short-acting octreotide for symptomatic carcinoid syndrome (CS) control in neuroendocrine tumor (NET) patients. Here we present patient-reported symptom data during DB and initial open-label (IOL) treatment. MATERIALS AND METHODS: Adults with NETs and CS history, with/without prior somatostatin analog use, were randomized to 16 weeks' DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks' IOL lanreotide. Patients recorded diarrhea and/or flushing frequency and severity daily by Interactive Voice (Web) Response System for 1 month prior to randomization and throughout the study. RESULTS: Of 115 patients randomized (n = 59 lanreotide, n = 56 placebo), 56 lanreotide and 45 placebo patients enrolled in the IOL phase. During DB treatment, least square (LS) mean percentages of days with moderate/severe diarrhea and/or flushing were significantly lower for lanreotide (23.4%) versus placebo (35.8%; LS mean difference [95% confidence interval]: -12.4 [-20.73 to -4.07]; p = .004). For DB lanreotide patients, average daily composite (frequency × severity) diarrhea scores improved significantly between DB and IOL treatment (mean difference: -0.71 [-1.20 to -0.22]; p = .005), and remained stable for diarrhea and/or flushing. For DB placebo patients, composite scores for diarrhea, flushing, and diarrhea and/or flushing improved significantly between DB and IOL treatment (mean differences: -1.07 [-1.65 to -0.49]; -1.06 [-1.93 to -0.19]; and -2.13 [-3.35 to -0.91]; all p ≤ .018). CONCLUSION: Improved diarrhea and flushing control in CS patients during 16-week lanreotide treatment was sustained during maintenance of lanreotide treatment for the 32-week IOL phase (48 weeks total). IMPLICATIONS FOR PRACTICE: This study prospectively collected daily patient-reported data on diarrhea and flushing from the ELECT trial to evaluate the direct impact of lanreotide depot on patients' relief of carcinoid syndrome symptoms. Treatment with lanreotide depot was associated with significant reductions in the percentages of days patients reported symptoms of diarrhea and flushing, as well as reductions in the frequency and severity of daily symptoms compared with placebo during 16 weeks of double-blind treatment. These improvements were sustained for 32 additional weeks of open-label lanreotide treatment (i.e., through week 48 of treatment), resulting in clinically meaningful, long-term symptom reduction.


Assuntos
Antineoplásicos/uso terapêutico , Diarreia/prevenção & controle , Rubor/prevenção & controle , Géis/uso terapêutico , Tumores Neuroendócrinos/tratamento farmacológico , Peptídeos Cíclicos/uso terapêutico , Somatostatina/análogos & derivados , Método Duplo-Cego , Seguimentos , Humanos , Tumores Neuroendócrinos/patologia , Prognóstico , Estudos Prospectivos , Somatostatina/uso terapêutico
7.
BMC Surg ; 17(1): 90, 2017 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-28800765

RESUMO

BACKGROUND: This study aimed to reveal the appropriate timing for the intravenous administration of flurbiprofen axetil for preventing mesenteric traction syndrome (MTS), caused by prostacyclin release. METHODS: In this prospective, randomized, clinical study, forty-five patients who were undergoing elective surgery for colorectal cancer via laparotomy were enrolled. Patients were randomly divided into 3 groups: a preoperative group (n = 16) receiving flurbiprofen axetil directly before surgery; a post-MTS group (n = 14) receiving following MTS onset; and a control group (n = 15) who were not administered flurbiprofen axetil. 6-keto-PGF1α, a stable metabolite of prostacyclin, levels were measured and mean blood pressures were recorded. RESULTS: In the preoperative group, 6-keto-PGF1α levels did not increase, blood pressure levels did not decrease, and no facial flushing was observed. In both the post-MTS and control groups, 6-keto-PGF1α levels increased markedly after mesenteric traction and blood pressure decreased significantly. The post-MTS group exhibited a faster decreasing trend in 6-keto-PGF1α levels and quick restore of the mean blood pressure, and the use of vasopressors and phenylephrine were lower than that in the control group. CONCLUSIONS: Even therapeutic administration of flurbiprofen axetil after the onset of MTS has also effects on MTS by suppressing prostacyclin production. TRIAL REGISTRATION: Clinical trial number: UMIN000009111 . (Registered 14 October 2012).


Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Flurbiprofeno/análogos & derivados , Rubor/tratamento farmacológico , Hemodinâmica/efeitos dos fármacos , Hipotensão/tratamento farmacológico , Complicações Intraoperatórias/tratamento farmacológico , Taquicardia/tratamento farmacológico , 6-Cetoprostaglandina F1 alfa/sangue , Idoso , Pressão Sanguínea/efeitos dos fármacos , Neoplasias Colorretais/cirurgia , Epoprostenol/antagonistas & inibidores , Epoprostenol/biossíntese , Feminino , Flurbiprofeno/administração & dosagem , Rubor/prevenção & controle , Humanos , Hipotensão/prevenção & controle , Infusões Intravenosas , Complicações Intraoperatórias/prevenção & controle , Laparotomia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Síndrome , Taquicardia/prevenção & controle
8.
Am J Health Syst Pharm ; 74(12): 898-903, 2017 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-28432049

RESUMO

PURPOSE: Results of a study to test the hypothesis that taking niacin simultaneously with different forms of aspirin would reduce the occurrence of niacin-induced flushing are reported. METHODS: Traditionally, taking enteral absorbed aspirin 30 minutes before a niacin dose has been shown to reduce flushing by 30-50% relative to nonuse of aspirin. The objective of the study was to evaluate the efficacy of enteral absorbed and orally dissolved aspirin, taken at the same time as niacin, in reducing the frequency of moderate-to-severe flushing. In a prospective, double-blind, placebo-controlled crossover trial, healthy adult male and female volunteers were asked to take aspirin or a placebo (both agents were taken in both orally dissolved and swallowed formulations) immediately before niacin administration. Subjects then self-evaluated flushing symptoms on a validated scale. RESULTS: Simultaneous administration of swallowed aspirin and niacin reduced moderate-to-severe flushing events by a mean of 36.1%, from 2.35 to 1.5 events per subject (p = 0.003), relative to event rates with use of niacin alone. In a subset of subjects who had experienced moderate-to-severe flushing symptoms despite taking swallowed aspirin, flushing in response to subsequent niacin use was decreased by 20.5% (p = 0.05) with coadministration of orally dissolved aspirin and by 18.0% with a regimen containing both orally dissolved and swallowed aspirin (p = 0.03). CONCLUSION: Novel regimens of niacin and aspirin, including orally dissolved aspirin, were effective in reducing niacin-induced flushing in a small sample of healthy adult volunteers.


Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Aspirina/administração & dosagem , Rubor/induzido quimicamente , Rubor/prevenção & controle , Niacina/administração & dosagem , Vasodilatadores/administração & dosagem , Adulto , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Rubor/diagnóstico , Humanos , Masculino , Niacina/efeitos adversos , Vasodilatadores/efeitos adversos
10.
Ann Allergy Asthma Immunol ; 115(1): 39-44, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25981840

RESUMO

BACKGROUND: Little is known about drug hypersensitivity reactions from antituberculosis drugs. OBJECTIVE: To determine the frequency, risk factors, and characteristics of immediate-type hypersensitivity reactions from first-line antituberculosis drugs and to evaluate the usefulness of a readministration protocol for culprit drugs in this group of patients. METHODS: The study population consisted of patients with tuberculosis who were hospitalized and treated in the authors' hospital in 2011. Demographics and disease and treatment characteristics of patients with immediate-type hypersensitivity from antituberculosis drugs were compared with the other patients. Culprit drugs were readministered gradually according to a defined protocol to patients with immediate-type hypersensitivity. RESULTS: Tree hundred seventy-nine patients were included in the study. Eighteen immediate-type hypersensitivity reactions were detected in 13 patients (3.43%). The only identified risk factor was female sex (odds ratio 4.085). Isoniazid, rifampicin, pyrazinamide, and ethambutol were readministered in 11 patients and rifampicin was readministered in 2 patients, with 6- to 8-step protocols for each drug. Only in 2 patients did allergic reactions with rifampicin develop during the procedure. In these patients, after treatment and complete remission of allergic symptoms, the last tolerated dose was administered and the protocol was completed with the same adjustments. CONCLUSION: Immediate-type allergic reactions from antituberculosis drugs are not rare and not related to disease or treatment characteristics. The protocols used in this study provide a useful and safe method for readministration of culprit drugs to patients with antituberculosis drug hypersensitivity.


Assuntos
Antituberculosos/efeitos adversos , Dessensibilização Imunológica , Hipersensibilidade a Drogas/etiologia , Hipersensibilidade Imediata/etiologia , Corticosteroides/uso terapêutico , Antituberculosos/administração & dosagem , Antituberculosos/uso terapêutico , Estudos de Casos e Controles , Esquema de Medicação , Hipersensibilidade a Drogas/tratamento farmacológico , Hipersensibilidade a Drogas/epidemiologia , Hipersensibilidade a Drogas/prevenção & controle , Feminino , Rubor/induzido quimicamente , Rubor/epidemiologia , Rubor/prevenção & controle , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Hipersensibilidade Imediata/tratamento farmacológico , Hipersensibilidade Imediata/epidemiologia , Hipersensibilidade Imediata/prevenção & controle , Masculino , Prevalência , Prurido/induzido quimicamente , Prurido/epidemiologia , Prurido/prevenção & controle , Fatores de Risco , Fatores Sexuais , Tuberculose/complicações , Tuberculose/tratamento farmacológico , Urticária/induzido quimicamente , Urticária/epidemiologia , Urticária/prevenção & controle
11.
Clin Ther ; 37(7): 1402-1419.e5, 2015 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-25999183

RESUMO

PURPOSE: In Phase III trials, delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) demonstrated significant efficacy and an acceptable safety profile in patients with relapsing-remitting multiple sclerosis. The purpose of the present study was to examine 2 potential mitigation strategies for flushing and gastrointestinal (GI) events associated with DMF treatment: aspirin (ASA) 325 mg pretreatment for flushing, and slow dose titration of DMF for flushing and GI events. METHODS: The 8-week study included 173 healthy volunteers randomized to 4 groups; 172 underwent dosing. The placebo group (n = 44) received placebo ASA 30 minutes before placebo DMF (weeks 1-4), then placebo DMF alone (weeks 5-8). The DMF without ASA group (n = 43) and the DMF with ASA group (n = 43) received placebo ASA or ASA, respectively, 30 minutes before DMF (weeks 1-4), then DMF alone (weeks 5-8); in both groups, DMF was dosed at 120 mg BID (week 1) and 240 mg BID (weeks 2-8). The slow dose titration DMF group (n = 42) received DMF 120 mg once daily (week 1), 120 mg BID (week 2), 240 mg in the morning/120 mg in the evening (week 3), and 240 mg BID (weeks 4-8). Subjects recorded information about flushing and GI-related events by using an eDiary and numerical rating scales. FINDINGS: Flushing and GI-related events were reported in all groups and were mostly rated as mild or moderate in severity. Flushing events were generally ~1 hour in duration and, for most subjects with flushing, initially occurred the first day of study treatment. The duration of GI-related events and time to first GI-related event varied by event type. ASA reduced the incidence, severity, and number of flushing events without affecting duration or time to first flushing event, and had no adverse effect on GI-related events. Dose titration of DMF had no significant effect on flushing or GI events. No subjects discontinued the study due to flushing events. One subject (2%) in the placebo group, 3 subjects (7%) in the DMF without ASA group, 6 subjects (14%) in the DMF with ASA group, and 2 subjects (5%) in the slow dose titration DMF group discontinued treatment because of GI events. IMPLICATIONS: ASA pretreatment may mitigate flushing associated with DMF, with no adverse effect on GI events. Dose titration of DMF did not have a significant effect on flushing or GI events and is being evaluated further in ongoing clinical trials. ClinicalTrials.gov identifier: NCT01568112.


Assuntos
Aspirina/administração & dosagem , Preparações de Ação Retardada/efeitos adversos , Fumarato de Dimetilo/efeitos adversos , Imunossupressores/administração & dosagem , Dor Abdominal/induzido quimicamente , Dor Abdominal/prevenção & controle , Adulto , Aspirina/uso terapêutico , Constipação Intestinal/induzido quimicamente , Constipação Intestinal/prevenção & controle , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/uso terapêutico , Diarreia/induzido quimicamente , Diarreia/prevenção & controle , Fumarato de Dimetilo/administração & dosagem , Fumarato de Dimetilo/uso terapêutico , Feminino , Rubor/induzido quimicamente , Rubor/prevenção & controle , Voluntários Saudáveis , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Distribuição Aleatória
12.
Nervenarzt ; 85(6): 720-6, 2014 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-24668400

RESUMO

After the approval of fumaric acid in February 2014 another first line agent is now available for the treatment of multiple sclerosis (MS). Along with the various beta interferon preparations, glatiramer acetate, teriflunomide and fumaric acid add to the repertoire of oral therapeutics for the initial treatment of relapsing remitting MS in daily practice. In order to employ these drugs in an individualized and precise medical manner and considering their efficacy and side effects, it seems worthwhile to learn the so far known mode of action and background history. Fumaric acid, as one of the newest drugs approved for MS, reveals the longest history as it was in use for decades as a treatment in psoriasis patients. Furthermore, fumaric acid is a good example for so far not extensively exploited option of drug reposition in medicine in general. The current review summarizes the outcomes of the clinical approval studies of fumaric acid in MS and discusses the dual mode of action, the immunomodulatory and tissue protective effect, as well as the reported adverse events under fumaric acid treatment. This review aims to serve an aid in the daily decision-making practice when choosing the baseline therapy for MS patients.


Assuntos
Rubor/induzido quimicamente , Fumaratos/administração & dosagem , Gastroenteropatias/induzido quimicamente , Nefropatias/induzido quimicamente , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Relação Dose-Resposta a Droga , Esquema de Medicação , Medicina Baseada em Evidências , Rubor/prevenção & controle , Gastroenteropatias/prevenção & controle , Humanos , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/efeitos adversos , Nefropatias/prevenção & controle , Esclerose Múltipla Recidivante-Remitente/complicações , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/efeitos adversos , Resultado do Tratamento
13.
Eur J Pharmacol ; 727: 1-7, 2014 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-24486398

RESUMO

GPR81, which exhibits a high degree of homology with GPR109a, has been recently identified as a lactate receptor. Similar to GPR109a, the activation of GPR81 by lactate suppresses lipolysis, suggesting that GPR81 may be a potential drug target for treating dyslipidemia. In addition, the fact that GPR81 is expressed only in adipocytes, whereas GPR109a is expressed in various tissues and cells, including Langerhans cells, which are considered responsible for flushing, indicates that targeting GPR81 could lead to the development of antidyslipidemia agents with a reduced risk of this side effect. However, the pharmacological role of GPR81 remains largely unclear, mainly because of the lack of potent and selective surrogate GPR81 agonists suitable for in vivo studies. In the present study, we showed that lactate-induced suppression of lipolysis in explants of white adipose tissue (WAT) depends on the presence of GPR81. We also performed high-throughput screening (HTS) and identified four novel chemical clusters as GPR81 agonists. Chemical optimization of aminothiazole derivatives led to the discovery of a lead compound with improved potency. The compound inhibited lipolysis in differentiated 3T3-L1 adipocytes. Finally, intraperitoneal administration of this compound suppressed lipolysis in mice at doses that did not cause cutaneous flushing. This is the first description of a 50nM GPR81 selective agonist with in vivo efficacy, without the side effect, i.e., flushing. These results suggest that GPR81 is an attractive drug target for treating dyslipidemia without the risk of flushing.


Assuntos
Adipócitos/efeitos dos fármacos , Tecido Adiposo Branco/efeitos dos fármacos , Rubor/prevenção & controle , Hipolipemiantes/farmacologia , Lipólise/efeitos dos fármacos , Receptores Acoplados a Proteínas G/agonistas , Tiazóis/farmacologia , Células 3T3-L1 , Adipócitos/metabolismo , Tecido Adiposo Branco/metabolismo , Animais , Relação Dose-Resposta a Droga , Descoberta de Drogas , Ensaios de Triagem em Larga Escala , Hipolipemiantes/administração & dosagem , Hipolipemiantes/síntese química , Injeções Intraperitoneais , Ácido Láctico/farmacologia , Masculino , Camundongos , Camundongos da Linhagem 129 , Camundongos Endogâmicos C57BL , Camundongos Knockout , Receptores Acoplados a Proteínas G/deficiência , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Relação Estrutura-Atividade , Tiazóis/administração & dosagem , Tiazóis/síntese química , Transfecção
14.
Internist (Berl) ; 55(2): 206-11, 2014 Feb.
Artigo em Alemão | MEDLINE | ID: mdl-24449139

RESUMO

A 59-year-old patient was admitted to hospital with recurrent flush symptoms and pathologically elevated 5-hydroxyindoleacetic acid (5-HIAA) levels in urine. A known cystic lesion of the liver which had been followed for years by ultrasound examinations and was regarded as a bland hepatic cyst was identified as a metastasis of a neuroendocrine neoplasm of the ileum. In two sequential surgical interventions the primary tumor with mesenteric lymph node metastases as well as the cystic liver metastasis could be resected. After surgical treatment an R1 situation at the mesenteric site and suspicious para-aortic lymph nodes remained. The long established treatment of factor-V Leiden mutation by anticoagulation with phenprocoumon was supplemented by deep subcutaneous injection of lanreotide autogel every 4 weeks. Currently, there is no evidence for progressive disease and the patient is without clinical signs of a carcinoid syndrome.


Assuntos
Cistos/diagnóstico , Cistos/prevenção & controle , Rubor/diagnóstico , Rubor/prevenção & controle , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/terapia , Síndrome do Carcinoide Maligno/diagnóstico , Síndrome do Carcinoide Maligno/terapia , Cistos/complicações , Diagnóstico Diferencial , Rubor/etiologia , Humanos , Neoplasias Hepáticas/complicações , Masculino , Síndrome do Carcinoide Maligno/complicações , Pessoa de Meia-Idade
15.
Masui ; 62(3): 309-14, 2013 Mar.
Artigo em Japonês | MEDLINE | ID: mdl-23544333

RESUMO

BACKGROUND: Mesenteric traction syndrome (MTS) is associated with facial flushing, hypotension and tachycardia. The ways to treat MTS are fluid replacement, administration of vasopressors and nonsteroidal anti-inflammatory drugs (NSAIDs) such as flurbiprofen. In order to stabilize the hemodynamics during operation, preventing MTS is more reasonable. Thus, we investigated the preventive effect of flurbiprofen on MTS, the only injectable formulation which can be used in Japan. METHODS: In a prospective randomized study, 24 patients undergoing elective colorectal surgery were assigned to two groups. In one group (n = 11 group F), flurbiprofen (1 mg x kg(-1), 50 mg max) was administered before surgery. In the second group (n = 13; group C), flurbiprofen was not administered. After laparotomy, presence of facial flushing and blood pressure reduction were compared. MTS is defined as facial flushing with concomitant blood pressure reduction. RESULTS: MTS occurred in no patients in group F, but in 11 patients in group C (84.6%, P < 0.05). In cases of the patients in which MTS appeared, facial flushing was observed at 5.9 +/- 5.2 min after starting mesenteric manipulation, and the mean reduction in blood pressure was 40.3% at 9.9 +/- 4.4 min after starting mesenteric manipulation. CONCLUSIONS: Our results indicate that pretreatment with flurbiprofen might prevent MTS.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Flurbiprofeno/uso terapêutico , Rubor/prevenção & controle , Hipotensão/prevenção & controle , Taquicardia/prevenção & controle , Idoso , Feminino , Humanos , Complicações Intraoperatórias/prevenção & controle , Masculino , Estudos Prospectivos , Síndrome
16.
J Clin Lipidol ; 7(2): 140-6, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23415433

RESUMO

BACKGROUND: Niacin, or vitamin B3, when used in high doses can significantly improve the levels of all major lipoproteins. Despite these benefits, the use of niacin is greatly limited secondary to benign yet bothersome cutaneous flushing primarily involving the face and upper extremities. Pretreatment with aspirin or other prostaglandin inhibitors has demonstrated significant reductions in niacin-induced flushing (NIF), but other treatment options are needed. Clinical and anecdotal evidence suggests the ingestion of pectin-containing fruits (eg, apple) mitigates NIF; however, clinical trials evaluating this are nonexistent. OBJECTIVE: That pretreatment with encapsulated apple pectin would limit the incidence, severity, time of initiation, and duration of NIF. METHODS: We enrolled 100 niacin-naïve subjects (n = 25 per group) and preteated them in a double-blind manner with apple pectin, apple pectin + aspirin, aspirin, or placebo, followed by a one-time 1000 mg dose of niacin extended-release (niacin ER). Subjects then assessed major flushing parameters hourly for the next 6 hours with a validated visual analog scale. RESULTS: Apple pectin and aspirin each significantly lowered the duration of NIF and produced nonsignificant but positive improvements in all other major flushing parameters compared with placebo. CONCLUSION: Apple pectin may potentially be an alternative to aspirin for the prevention of NIF. Larger trials are needed to further evaluate the benefit of pectin on NIF.


Assuntos
Rubor/dietoterapia , Hipolipemiantes/efeitos adversos , Malus/metabolismo , Niacina/efeitos adversos , Pectinas/uso terapêutico , Adolescente , Adulto , Idoso , Anti-Inflamatórios não Esteroides/uso terapêutico , Aspirina/uso terapêutico , Método Duplo-Cego , Feminino , Rubor/induzido quimicamente , Rubor/prevenção & controle , Humanos , Masculino , Pessoa de Meia-Idade , Efeito Placebo , Adulto Jovem
17.
Expert Opin Pharmacother ; 13(9): 1345-62, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22607011

RESUMO

INTRODUCTION: Although treatment with statins reduces cardiovascular (CV) events in patients with dyslipidemia, a residual 60 - 70% CV risk remains. This CV risk may be inversely related to high-density lipoprotein-cholesterol (HDL-C). Interest in niacin has re-emerged because of its HDL-C raising effects. The flushing associated with niacin which has previously affected patient compliance can now be significantly blocked with laropiprant (LRPT). AREAS COVERED: This review aims to assess the efficacy, clinical effectiveness and safety of extended-release niacin (ERN) with LRPT. The authors searched PubMed and MEDLINE for literature published between January 2006 and November 2011, for efficacy, clinical effectiveness and safety reports of ERN with LRPT. EXPERT OPINION: Niacin has been shown to prevent CV events, reduce mortality and has beneficial effects on vascular endothelial function. Evidence suggests that this is due to its broad-spectrum lipid altering properties, including lowering lipoprotein (a) (Lp(a)), and its pleiotropic actions. While side effects associated with niacin have limited its use in the past, the extended-release formulations and co-administration of LRPT have increased its tolerability, particularly by reducing flushing. The authors advise that ERN should be used in patients with a high risk of cardiovascular disease, who have failed to reach conventional targets.


Assuntos
Doenças Cardiovasculares/prevenção & controle , Dislipidemias/tratamento farmacológico , Rubor/prevenção & controle , Hipolipemiantes/administração & dosagem , Indóis/administração & dosagem , Niacina/administração & dosagem , Animais , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/etiologia , Preparações de Ação Retardada , Dislipidemias/sangue , Dislipidemias/complicações , Medicina Baseada em Evidências , Rubor/induzido quimicamente , Humanos , Hipolipemiantes/efeitos adversos , Hipolipemiantes/farmacocinética , Indóis/efeitos adversos , Indóis/farmacocinética , Lipídeos/sangue , Niacina/efeitos adversos , Niacina/farmacocinética , Guias de Prática Clínica como Assunto , Resultado do Tratamento
18.
Expert Opin Drug Saf ; 11(1): 151-9, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22133050

RESUMO

INTRODUCTION: Niacin is one of the oldest drugs used in the treatment of dyslipidemia. Previously its use has been limited because of excessive flushing. Now an agent laropiprant (LRP) has been developed, which blocks the flushing pathway. Therefore, it is time to collate available information to assess the safety and tolerability of combining niacin with LRP. AREAS COVERED: The authors searched PubMed and MEDLINE for literature published between January 2006 and July 2011, for safety and tolerability reports of extended-release niacin (ERN) with LRP. EXPERT OPINION: The addition of LRP to ERN, by reducing the side effect 'flushing', may enable lipidologists and physicians to use niacin more widely as part of lipid modification therapy, especially since the combination can be safely added to statins. However, it has to be accepted that the addition of LRP does not completely abolish flushing. The favorable safety profile supports the use of LRP to achieve higher therapeutic dosing of niacin.


Assuntos
Hipolipemiantes/efeitos adversos , Indóis/farmacologia , Niacina/efeitos adversos , Animais , Preparações de Ação Retardada , Combinação de Medicamentos , Dislipidemias/tratamento farmacológico , Rubor/induzido quimicamente , Rubor/prevenção & controle , Humanos , Hipolipemiantes/administração & dosagem , Hipolipemiantes/uso terapêutico , Indóis/administração & dosagem , Niacina/administração & dosagem , Niacina/uso terapêutico
19.
Curr Vasc Pharmacol ; 9(4): 385-400, 2011 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-21314635

RESUMO

AIMS: Treatment with statins has significantly reduced cardiovascular morbidity and mortality, an effect attributed to both the low-density lipoprotein cholesterol (LDL-C) lowering capacity and the pleiotropic actions of these drugs. However, residual risk remains even after intense LDL-C lowering. Therefore, additional treatment with lipid-lowering drugs which improve other lipid parameters and have favourable non-lipid effects may be of clinical value. The aim of the present article is to review the actions of nicotinic acid and comment on the limitations and possible benefits of this drug in clinical practice. METHODS: Relevant articles were identified through a Pubmed search up to July 2010. RESULTS: Nicotinic acid (niacin) improves the lipid profile and has been associated with reduction in morbidity and mortality from cardiovascular disease. This favourable outcome may be due to several beneficial actions of this drug, such as antithrombotic, anti-inflammatory and antioxidant. However, its use has been limited due to side effects, especially flushing. A novel formulation with a prostaglandin D2 receptor antagonist (laropiprant) appears to substantially decrease the frequency and intensity of flushing, without affecting the other properties of niacin. Some concerns regarding treatment with nicotinic acid include impaired glucose metabolism and elevations in uric acid and homocysteine levels. CONCLUSION: Nicotinic acid is a safe supplementary (to statins) lipid lowering agent which may also improve cardiovascular outcomes. Whether its combination with laropiprant will be proved equally effective and more favourable in terms of adverse effects remains to be established by large clinical trials.


Assuntos
HDL-Colesterol/efeitos dos fármacos , Hipolipemiantes/farmacologia , Niacina/farmacologia , Animais , HDL-Colesterol/sangue , Quimioterapia Combinada , Rubor/induzido quimicamente , Rubor/prevenção & controle , Glucose/metabolismo , Homocisteína/metabolismo , Humanos , Hipolipemiantes/efeitos adversos , Indóis/administração & dosagem , Indóis/farmacologia , Niacina/efeitos adversos , Receptores Imunológicos/antagonistas & inibidores , Receptores de Prostaglandina/antagonistas & inibidores , Ácido Úrico/metabolismo
20.
J Clin Pharmacol ; 51(3): 406-12, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20484612

RESUMO

This open-label study evaluated the influence of hepatic insufficiency on the pharmacokinetics of laropiprant (LRPT), a prostaglandin D(2) receptor-1 antagonist, to guide clinicians in the event of inadvertent dosing in patients with hepatic insufficiency. A single oral 40-mg dose of LRPT was administered to 8 patients with moderate hepatic insufficiency and 8 healthy control participants matched for important baseline characteristics. Blood samples were collected predose and up to 96 hours postdose to assess LRPT pharmacokinetics. No clinically significant effect of hepatic insufficiency would be declared if the 90% confidence interval (CI) for the estimated geometric mean ratio (GMR; hepatic insufficiency patients/healthy participants) of AUC(0-∞) was contained within the prespecified bounds of (0.50-3.00). Estimated GMRs of AUC(0-∞) and C(max) (90% CIs) were 2.78 (1.71, 4.50) and 2.17 (1.33, 3.53), respectively. The median time to C(max) and apparent terminal t(1/2) of LRPT were comparable between the 2 populations (P > .100). Single-dose LPRT 40 mg was generally well tolerated in all patients. The plasma pharmacokinetics of a single 40-mg oral dose of LRPT is not similar between patients with moderate hepatic insufficiency and matched healthy participants. The GMR (90% CI) of AUC(0-∞) for patients with moderate hepatic insufficiency versus matched controls was 2.78 (1.71, 4.50).


Assuntos
Insuficiência Hepática/metabolismo , Indóis/farmacocinética , Receptores Imunológicos/antagonistas & inibidores , Receptores de Prostaglandina/antagonistas & inibidores , Feminino , Rubor/induzido quimicamente , Rubor/prevenção & controle , Meia-Vida , Humanos , Indóis/efeitos adversos , Indóis/sangue , Masculino , Pessoa de Meia-Idade , Niacina/efeitos adversos , Isoformas de Proteínas/antagonistas & inibidores , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA